VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.30) per share which beat the an

Exploratory analyses of patients with very severe social anxiety disorder demonstrated nominally sta

Repeat dose of fasedienol demonstrated favorable safety and tolerability similar to single dose Effi

The Company views Vistagen shares as undervalued and welcomes constructive engagement with its leade

NORTH PALM BEACH, Fla., Aug. 04, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the

SOUTH SAN FRANCISCO, Calif., July 31, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clini

Vistagen Therapeutics, Inc. (VTGN) Discusses PALISADE-4 Phase III Results and Post-Hoc Analyses in S

Vistagen Inc. (NASDAQ:VTGN) on Monday reported that its Phase 3 PALISADE-4 trial of intranasal fased

Vistagen's Phase 3 fasedienol trial missed its main endpoint, but the company found a severe-pat

Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 242.5% to $2.77 during Tuesday&#

US stocks traded higher, Nasdaq up 150 points. Dow up 0.02%, Nasdaq up 0.68%, S&P 500 up 0.28%.

US stocks mixed, Dow falls 0.2%. Leading sectors: tech up 1%, real estate down 1.4%. S&P 500 up

PALISADE-4 was a U.S. multi-center, randomized, double-blind, placebo-controlled Phase 3 clinical tr

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biophar

VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.37) per share which missed the

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biophar

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biophar

Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm PR Newswire NEW YO

NEW YORK, June 1, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is invest

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen to Participate in Jefferies 2026 Global Healt

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biophar

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen, a late clinical-stage biopharmaceutical comp

Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biophar

Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biophar

NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is

SAN FRANCISCO, April 28, 2026 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises Vistagen Therap

Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biophar

New York, New York--(Newsfile Corp. - April 20, 2026) - Kuehn Law, PLLC, a shareholder litigation la

Helus Pharma (Cybin) shares fall after Phase 2 anxiety drug results show symptom improvement, but pr

VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.45) per share which missed the

Jefferies analyst Andrew Tsai downgrades Vistagen Therapeutics (NASDAQ:VTGN) from Buy to Hold and

Vistagen shares plunge after its Phase 3 fasedienol trial for social anxiety failed to meet the prim

Study did not demonstrate statistically significant improvement on primary endpoint of reduction in

Research supports the product candidate's non-hormonal, non-systemic, rapidly-acting effects on

VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.54) per share which missed the

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience wit